anything remark of ZERO logic. keep it up.
Patent ≠ Market Approval – Just because Imugene has a patent in India doesn’t mean CF33 can be sold there. It still needs clinical trials and regulatory approval from India’s drug authority (CDSCO) before making any revenue.
some home work for you
what is healthcare spending per capita in India and why is this announcement completely fluff and redundant?
Ann: Imugene Granted India Patent for Oncolytic Virotherapy CF33, page-36
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $77.89M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.3¢ | $1.990M | 7.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 209631 | 9 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |